Author

V. Besada

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Biochemistry· 1 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:proteomics· 5 Approach:experimental assay· 3 Organism:human· 3 Research Focus:protein folding & dynamics· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

L. J. Gonzalez· 5 shared Y. Ramos· 5 shared J. R. Wisniewski· 4 shared A. Rodriguez-Ulloa· 3 shared Y. Perera· 3 shared A. C. Ramon· 2 shared D. Vazquez-Blomquist· 2 shared G. V. Perez· 2 shared

Activity by Year

2021-2022 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

L. J. Gonzalez

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Proteomics and phosphoproteomics profiling of the co-formulation of type I and II interferons, HeberFERON, in the glioblastoma-derived cell line U-87 MG

D. Vazquez-Blomquist, A. Hardy-Sosa, S. C. Baez, V. Besada, S. Palomares, O. Guirola, Y. Ramos, J. R. Wisniewski, L. J. Gonzalez, I. Bello-Rivero

This study uses proteomic and phosphoproteomic analyses to investigate the effects of HeberFERON on U-87 MG glioblastoma cells, identifying key pathways and phosphosites involved in antiproliferative responses.

bioRxiv · Oct 3, 2022 · PreprintCancer Biology

Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300

M. Rosales, G. V. Perez, A. C. Ramon, Y. Cruz, A. Rodriguez-Ulloa, V. Besada, Y. Ramos, D. Vazquez-Blomquist, E. Caballero, D. Aguilar, L. J. Gonzalez, K. Zettl, J. R. Wisniewski, Y. Ke, Y. Perera, S. E. Perea

This study investigates the anti-proliferative and proapoptotic effects of the CK2 inhibitor CIGB-300 on AML cells and identifies its molecular targets.

bioRxiv · May 19, 2021Cancer Biology

In-solution buffer-free digestion for the analysis of SARS-CoV-2 RBD proteins allows a full sequence coverage and detection of post-translational modifications in a single ESI-MS spectrum

L. A. Espinosa, Y. Ramos, I. Andujar, E. O. Torres, G. Cabrera, A. Martin, D. Gonzalez, G. Chinea, M. Becquet, I. Gonzalez, C. Canaan-Haden, E. Nelson, G. Rojas, B. Perez-Masson, D. Perez-Martinez, , L. J. Gonzalez

This paper introduces an in-solution buffer-free digestion method for analyzing SARS-CoV-2 RBD proteins, achieving full sequence coverage and detecting post-translational modifications in a single ESI-MS spectrum.

bioRxiv · May 10, 2021 · PreprintBiochemistry

Gel Electrophoresis/Electroelution Sorting Fractionator combined with Filter Aided Sample preparation (FASP) for deep proteomic analysis.

Y. Ramos, A. Almeida, J. Carpio, A. Rodriguez-Ulloa, Y. Perera, L. J. Gonzalez, J. R. Wisniewski, V. Besada

The paper introduces a new device for protein fractionation and demonstrates its effectiveness in increasing protein identification in proteomic analysis.

bioRxiv · Apr 16, 2021Bioengineering

Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945

M. Rosales, A. Rodriguez-Ulloa, V. Besada, A. C. Ramon, G. V. Perez, Y. Ramos, O. Guirola, L. J. Gonzalez, K. Zettl, J. R. Wisniewski, Y. Perera, S. E. Perea

This study examines the phosphoproteomic changes in AML cell lines treated with CX-4945, identifying key biological processes and pathways affected by CK2 inhibition.

bioRxiv · Jan 4, 2021Cancer Biology